Considering the limited efficacy of current anti-angiogenic monotherapies in GBM and other solid tumors, OR51E1 presents a promising complementary therapeutic target for modulating tumor vasculature and potentially enhancing therapeutic outcomes. Here, OR51E1 is linked to neoplasm.